Caladrius Biosciences

Lisata Therapeutics, Inc. develops biopharmaceuticals. It is engaged in the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. It is designed to modify the tumor microenvironment by activating a novel uptake pathway that allows anti-cancer drugs to penetrate solid tumors more effectively. The company is headquartered in Basking Ridge, NJ.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Lisata Therapeutics, Inc. is engaged in the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Its product, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to target and penetrate tumors. It also actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs more efficiently penetrating and accumulating in the tumor, while normal tissues are unlikely to be affected. The company was founded in 1980 and is headquartered in Basking Ridge, NJ.

BASKING RIDGE, N.J., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease, today announced that David J. Mazzo, PhD, President and CEO of Caladrius, will be presenting a corporate overview at the upcoming 2022 BIO CEO & Investor Conference being held at the Marriott Marquis in NYC on February 14-15 and virtually through the 17th.

Caladrius Biosciences to Present at the BIO CEO & Investor Conference

BASKING RIDGE, N.J., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease, today announced its participation in several industry and investor events. All presentations are pre-recorded and available on-demand through the online conference platforms.

Caladrius Biosciences Announces Participation in Upcoming Conferences in January 2022

Flotek Industries

Gran Tierra Energy

Idera Pharmaceuticals

Penny stocks to buy for under $2 The post Hot Penny Stocks For 2022 To Buy For Under $2 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Penny Stocks For 2022 To Buy For Under $2

Caladrius Biosciences Inc.'s (CLBS) CEO David Mazzo on Q3 2021 Results - Earnings Call Transcript

BASKING RIDGE, N.J., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that the Company will report its financial results for the three months ended September 30, 2021, on Thursday, November 4, 2021, at 4:30 p.m. (ET). To join the live conference call, please refer to the dial-in information provided below.

Caladrius Biosciences to Host Third Quarter 2021 Financial Results Conference Call on Thursday, November 4th at 4:30 p.m. Eastern Time

BASKING RIDGE, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that David J. Mazzo, PhD, President and CEO of Caladrius, will provide a corporate update and participate in one-on-one investor meetings at the H.C. Wainwright 23rd Annual Global Investment Conference to be held September 13-15, 2021.

Caladrius Biosciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

BASKING RIDGE, N.J., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced the appointment of Dr. Kristen K. Buck as the Company's Chief Medical Officer (“CMO”).

Caladrius Biosciences Announces Appointment of Kristen K. Buck, M.D.

Caladrius Biosciences' (CLBS) CEO David Mazzo on Q2 2021 Results - Earnings Call Transcript

Caladrius Biosciences, Inc. (CLBS) delivered earnings and revenue surprises of 33.33% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Caladrius Biosciences, Inc. (CLBS) Reports Q2 Loss, Misses Revenue Estimates

Conference call begins today at 4:30 p.m. Eastern Time Conference call begins today at 4:30 p.m. Eastern Time

Caladrius Biosciences Reports Second Quarter 2021 Financial Results and Provides Business Update

BASKING RIDGE, N.J., July 29, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that the Company will report its financial results for the three months ended June 30, 2021, on Thursday, August 5, 2021, at 4:30 p.m. (ET). To join the live conference call, please refer to the dial-in information provided below.

Caladrius Biosciences to Host Second Quarter 2021 Financial Results Conference Call on Thursday, August 5, 2021 at 4:30 p.m. Eastern Time

BASKING RIDGE, N.J., July 22, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that its President and CEO, David J. Mazzo, PhD, will be presenting virtually at the Zooming with LD event on Thursday, July 29, 2021, at 10:00am Pacific Time/1:00pm Eastern Time. The presentation will be webcast live via the link below on the Investors & News section of the Company's website https://ir.caladrius.com.

Caladrius Biosciences to Present at Zooming with LD

The FDA has signed off Caladrius Bioscience Inc's (NASDAQ: CLBS) investigational new drug application for the study of CLBS201 for the treatment of diabetic kidney disease ("DKD"). The company plans to initiate a Phase 1/2 proof-of-concept study of CLBS201 within the next several months.

Caladrius Bioscience To Start Testing Its CD34+ Cell Therapy in Diabetic Kidney Disease

FDA authorizes new IND for the study of CLBS201 in patients with reduced kidney function FDA authorizes new IND for the study of CLBS201 in patients with reduced kidney function

Caladrius Biosciences to Assess its CLBS201 CD34+ Cell Therapy in Diabetic Kidney Disease

Presentation begins today at 10:30 a.m. Eastern time Presentation begins today at 10:30 a.m. Eastern time

Caladrius Biosciences to Present at Noble Capital Markets Virtual Investor Forum during the 16th Annual World Stem Cell Summit

Adverum Biotechnologies

InflaRx

There are some investors who invest in U.S.-listed stocks that are trading below their liquidation values because they believe they can gain from these allocations after the market has reappraised the share prices to near or above the liquidation value.

A Trio of Net Current Asset Value Stock Picks

BASKING RIDGE, N.J., June 01, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced its participation in several industry and investor events:

Caladrius Biosciences Announces Participation in Upcoming Conferences in June 2021

Cassava Sciences Inc

Caladrius Biosciences Inc (NASDAQ: CLBS) has received $1.4 million in non-dilutive funding as an approved participant of the Technology Business Tax Certificate Transfer Program sponsored by the New Jersey Economic Development Authority. The Program enables qualifying companies to sell a percentage of their New Jersey net operating losses and research and development tax credits to unrelated qualifying corporations.

Caladrius Biosciences, Cassava Sciences Secure Non-Dilutive Funding For Product Development

BASKING RIDGE, N.J., May 12, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that it has received $1.4 million in non-dilutive funding as an approved participant of the Technology Business Tax Certificate Transfer Program (the “Program”) sponsored by the New Jersey Economic Development Authority (NJEDA). The Program enables qualifying New Jersey-based biotechnology or technology companies to sell a percentage of their New Jersey net operating losses (“NOLs”) and research and development tax credits to unrelated qualifying corporations.

Caladrius Biosciences Receives $1.4 Million of Non-Dilutive Capital Through New Jersey Technology Business Tax Certificate Transfer Program

Caladrius Biosciences, Inc. (CLBS) CEO David Mazzo on Q1 2021 Results - Earnings Call Transcript

Caladrius Biosciences, Inc. (CLBS) delivered earnings and revenue surprises of -111.11% and -100.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Caladrius Biosciences, Inc. (CLBS) Reports Q1 Loss, Lags Revenue Estimates

BASKING RIDGE, N.J., April 29, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that the Company will report its financial results for the three months ended March 31, 2021 on Thursday, May 6, 2021 at 4:30 p.m. (ET). To join the live conference call, please refer to the dial-in information provided below.

Caladrius Biosciences to Host First Quarter 2021 Financial Results Conference Call on Thursday, May 6, 2021 at 4:30 p.m. Eastern Time

Investors need to pay close attention to Caladrius Biosciences (CLBS) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Caladrius Biosciences (CLBS) Stock?

Caladrius Biosciences, Inc. (CLBS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Caladrius Biosciences, Inc. (CLBS) Upgraded to Buy: What Does It Mean for the Stock?

BASKING RIDGE, N.J., March 03, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, announces that management will present a company overview and hold virtual investor meetings at the H.C. Wainwright Global Life Sciences Virtual Conference being held March 9-10, 2021.

News for Caladrius Biosciences Stock (CLBS)